scholarly journals TCT-577 Revascularization Strategies for Patients with Multiple Vessel Coronary Disease and Unprotected left main. Mid term Results from a Prospective, Multicenter and Controlled Argentina Registry with a Cobalt- Chromium Rapamycin Eluting Stent, FIREBIRD 2® (ERACI 4)

2014 ◽  
Vol 64 (11) ◽  
pp. B167-B168 ◽  
Author(s):  
Carlos Fernandez-Pereira ◽  
Ignacio Rifourcat ◽  
Juan Mieres ◽  
Carlos Haiek ◽  
Omar Santaera ◽  
...  
Keyword(s):  
Coronary Disease ◽  
Cobalt Chromium ◽  
Left Main ◽  
Mid Term Results

Deleterious impact of diabetes mellitus on early and mid-term results after stent implantation in left main coronary disease

2010 ◽  
Vol 11 (3) ◽  
pp. 209
Author(s):  
José F Díaz ◽  
Carlos Sanchez-Gonzalez ◽  
Juan C. Fernandez-Guerrero ◽  
Manuel Jimenez ◽  
Rosa Cardenal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Coronary Disease ◽  
Stent Implantation ◽  
Left Main ◽  
Mid Term Results

Rapamycin-eluting stents for the treatment of unprotected left main coronary disease

2004 ◽  
Vol 148 (3) ◽  
pp. 481-485 ◽  
Author(s):  
Jose Suarez de Lezo ◽  
Alfonso Medina ◽  
Manuel Pan ◽  
Antonio Delgado ◽  
José Segura ◽  
...  
Keyword(s):  
Coronary Disease ◽  
Left Main

scholarly journals 1116-8 Early and mid-term results of cypher stents in unprotected left main

2004 ◽  
Vol 43 (5) ◽  
pp. A21 ◽  
Author(s):  
Alaide Chieffo ◽  
Dejan Orlic ◽  
Flavio Airoldi ◽  
Iassen Michev ◽  
Matteo Montorfano ◽  
...  
Keyword(s):  
Left Main ◽  
Mid Term Results

scholarly journals Current diagnosis and management of left main coronary disease

2010 ◽  
Vol 38 (4) ◽  
pp. 420-428 ◽  
Author(s):  
Joanna Chikwe ◽  
Michael Kim ◽  
Andrew B. Goldstone ◽  
Arzhang Fallahi ◽  
Thanos Athanasiou
Keyword(s):  
Coronary Disease ◽  
Left Main ◽  
Diagnosis And Management

scholarly journals One-Year Follow-Up Results From the Observational, Multicenter, Prospective, and Controlled Registry: The WALTZ All-Comers Study

2019 ◽  
Vol 13 ◽  
pp. 117954681985405 ◽  
Author(s):  
Alfredo E Rodriguez ◽  
Miguel Larribau ◽  
Carlos Fernandez-Pereira ◽  
Jorge Iravedra ◽  
Omar Santaera ◽  
...  
Keyword(s):  
Primary Endpoint ◽  
Cardiac Death ◽  
Risk Scores ◽  
Exclusion Criterion ◽  
Cobalt Chromium ◽  
Left Main ◽  
Cardiac Events ◽  
Vessel Disease ◽  
Coronary Stent Implantation

The aim of this study was to evaluate 1-year follow-up results in an all “comers” population treated with a new cobalt chromium bare-metal stent (BMS) design. Since August 2016 to March 2017, 201 (9.7% of screening population) consecutive patients undergoing coronary stent implantation in 11 centers in Argentina were prospectively included in our registry. The inclusion criteria were multiple-vessel disease and/or unprotected left main disease, acute coronary syndromes (ACS) with at least one severe (⩾70%) stenosis in any of major epicardial vessel. In-stent restenosis, protected left main stenosis, or impossibility to receive dual-antiplatelet therapy was an exclusion criterion. Major adverse cardiac events (MACE) were the primary endpoint and included cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR); also, all components of the primary endpoint were separately analyzed. Completeness of revascularization was analyzed as post hoc data using residual SYNTAX or ERACI risk scores. Demographic characteristics showed that 6.5% of patients were very elderly, 22.5% have diabetes, 47% have multiple-vessel disease, 67% have ACS, and 32% have ST elevation MI. At a mean of 376 ± 18.1 days of follow-up, MACE was observed in 10.4% of patients: death + MI + cardiovascular accident (CVA) in 3% (6 of 201) and cardiac death + MI + CVA in 1.5% (3 of 201). Residual ERACI score ⩽5 was associated with 98% of event-free survival ( P < .04). In conclusion, this prospective, multicenter, and observational all-comers registry with this novel BMS design showed a low incidence of adverse events at 1 year mainly due to coronary restenosis.

Sign in / Sign up

Export Citation Format

Share Document